Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon share price today rose 3% after Biocon Biologics received US FDA approval for diabetes drug Kirsty, the first interchangeable biosimilar to NovoLog in the US. Get latest updates on Biocon ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...